Stock Events

Telesis Bio 

$2.81
24
-$0.03-1.07% Friday 19:54

Statistics

Day High
2.85
Day Low
2.26
52W High
18.54
52W Low
1.27
Volume
33,185
Avg. Volume
1,508,065
Mkt Cap
6.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Next
-7.62
-5.08
-2.54
0
Expected EPS
-5.3
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TBIO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.93B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Telesis Bio's technologies.
Pacific Biosciences of California
PACB
Mkt Cap373.36M
Pacific Biosciences offers long-read sequencing technologies, competing with Telesis Bio in the genomic sequencing market.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is involved in gene editing, a direct competitor to Telesis Bio's gene editing and engineering solutions.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the genome editing field, making it a competitor to Telesis Bio in the development of gene editing technologies.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is a leading gene editing company, competing with Telesis Bio in the CRISPR/Cas9 gene editing space.
Twist Bioscience
TWST
Mkt Cap2.53B
Twist Bioscience specializes in synthetic DNA, directly competing with Telesis Bio in the synthetic biology and gene synthesis market.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics focuses on genomic medicine, including gene editing, competing in the same space as Telesis Bio.
Beam Therapeutics
BEAM
Mkt Cap2.2B
Beam Therapeutics is involved in base editing, a form of gene editing, positioning it as a competitor to Telesis Bio in the gene editing technology sector.
Adaptive Biotechnologies
ADPT
Mkt Cap693.12M
Adaptive Biotechnologies is focused on the immune-driven medicine space, indirectly competing with Telesis Bio by offering complementary and competing genomic and diagnostic solutions.

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Show more...
CEO
Employees
101
Country
US
ISIN
US1920032000

Listings